Abstracts tagged "Cardiovascular disease"

Abstract Number: L01 • 2018 ACR/ARHP Annual Meeting
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Neus Quilis¹, Laura Ranieri², Jose Sanchez-Paya² and Mariano Andrés², ¹Hospital Universitario del Vinalopó, Elche, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: The recent CARES trial findings have contributed to the controversy around the development of cardiovascular (CV) events in gouty patients using febuxostat (FBX). In…
Abstract Number: L05 • 2018 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study
Maya H. Buch¹, Bara Erhayiem², Graham Fent², Paul Baxter³, Elizabeth M.A. Hensor⁴, Adam McDiarmid², Peter Swoboda⁵, Ananth Kidambi², David Ripley², Pankaj Garg², Sarah Horton⁴, Raluca Bianca Dumitru⁴, Kamran Naraghi⁴, John Greenwood⁶, Paul Emery⁷, Sue Pavitt⁸ and Sven Plein², ¹Leeds Institute of Rheumatic & Musculosekeltal Medicine, University of Leeds & NIHR Biomedical Research Centre, Leeds, United Kingdom, ²Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Cardiovascular & Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Cardiovascular And Metabolic Medicinee, University of Leeds, Leeds, United Kingdom, ⁷University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁸Leeds School of Dentistry, University of Leeds, Leeds, United Kingdom
Background/Purpose: We previously reported abnormal cardiac MRI (CMR)-determined aortic stiffness in patients with early, treatment-naive RA1,2. We now report on whether this vascular stiffness is…
Abstract Number: 200 • 2018 ACR/ARHP Annual Meeting
Validation of the Ers-RA Risk Score in a Dutch Population
Milad Baniaamam¹ and Michael Nurmohamed², ¹Department of rheumatology, Amsterdam Rheumatology immunology Center | Reade and VU University Medical Center Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: The most frequent cause of death in patients with chronic rheumatoid arthritis (RA) is of cardiovascular (CV) origin. CV risk prediction scores in the…
Abstract Number: 512 • 2018 ACR/ARHP Annual Meeting
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study
Maria Auxiliadora Martin¹, Santos Castañeda², Carlos González-Juanatey³, Fernando Sánchez-Alonso⁴, María Carmen García-Gómez⁵, R López-González⁶, Jesus Babio⁷, Antonio Juan-Mas⁸, María P Moreno-Gil⁹, Olga Sanchez-González¹⁰, Montserrat Romera¹¹, Jose A Pinto-Tasende¹², Jose A Piqueras¹³, Dolores Fábregas¹⁴, Javier Llorca¹⁵ and Miguel Angel González-Gay¹⁶, ¹Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ²Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ³Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, ⁴Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ⁶Rheumatology, Complejo Hospitalario de Zamora. Spain, Zamora, Spain, ⁷Rhaumatology, H General de Cabueñes, Gijon, Spain, ⁸Division of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, Spain, ⁹Division of Rheumatology, Hospital San Pedro de Alcántara, Cáceres, Spain, ¹⁰Division of Rheumatology, Hospital del Sureste, Madrid, Spain, ¹¹Division of Rheumatology, Hospital de Bellvitge, Barcelona, Spain, ¹²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹³Division of Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, ¹⁴Division of Rheumatology, Hospital de Barbastro, Huesca, Spain, ¹⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, ¹⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD)…
Abstract Number: 873 • 2018 ACR/ARHP Annual Meeting
General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
Kenneth Saag¹, Michael A. Becker², William B. White³, Andrew Whelton⁴, Jeffrey Borer⁵, Philip Gorelick⁶, Barbara Hunt⁷, Majin Castillo⁷ and Lhanoo Gunawardhana⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Chicago Pritzker School of Medicine, Chicago, IL, ³Cardiology, University of Connecticut School of Medicine, Farmington, CT, ⁴Johns Hopkins University School of Medicine, Hunt Valley, MD, ⁵State University of New York Downstate Medical Center, Brooklyn, NY, ⁶Michigan State University College of Human Medicine, Grand Rapids, MI, ⁷Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: The cardiovascular (CV) safety study CARES has the longest study duration of any randomized controlled trial in patients (pts) with gout and CV disease.…
Abstract Number: 1615 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Moa Lee¹, Rishi J. Desai², Yinzhu Jin³, Gregory Brill¹, Alexis Ogdie⁴ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease is a major comorbidity in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Increasing evidence suggests a potential reduction in the risk…
Abstract Number: 2217 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics of Early Onset Gout in Outpatient Setting
Yan Li¹, Paramarajan Piranavan¹, Devi Sundaresan² and Robert A. Yood³, ¹Internal Medicine, St. Vincent Hospital, Worcester, MA, ²Research, Reliant Medical Group, Worcester, MA, ³Reliant Medical Group, Worcester, MA
Background/Purpose: There has been an increase in the prevalence of gout over the past two decades, with increasing number of patients presenting at younger age.…
Abstract Number: 2964 • 2018 ACR/ARHP Annual Meeting
Detection of Uric Acid Crystals in the Vasculature of Patients with Gout Using Dual-Energy Computed Tomography
Sharon Barazani¹, WeiWei Chi², Renata Pyzik³, Adam Jacobi⁴, Tom O'Donnell⁵, Zahi Fayad³, Venkatesh Mani³ and Yousaf Ali², ¹Medical School, Icahn School of Medicine at Mount Sinai, New York, NY, ²Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Translational and Molecular Imaging Institute (TMII), Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Siemens Healthcare, New York, NY
Background/Purpose: Many recent studies have shown an association between gout and increased cardiovascular risk, however the mechanism by which this occurs is unclear. Dual-Energy Computed…
Abstract Number: 213 • 2018 ACR/ARHP Annual Meeting
Excessive Risk of Major Cardiovascular Events in Sero-Positive Rheumatoid Arthritis and in Patients with Active Disease
Annette de Thurah^1,2, Ina Trolle Andersen³, Andreas Bugge Tingaard⁴, Josephine Therkildsen⁵, Anders Hammerich Riis³, Morten Böttcher⁵ and Ellen-Margrethe Hauge^6,7, ¹Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ³Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, ⁴Department of Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁵Cardiology, Regional Hospital of Herning, Herning, Denmark, ⁶Department of Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁷Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for the development of cardiovascular disease (CVD). However, the influence of RA on the prognosis after…
Abstract Number: 513 • 2018 ACR/ARHP Annual Meeting
Low Serum IGF1 Is Associated with Higher Cardiovascular Morbidity in the Middle-Aged Women with Rheumatoid Arthritis
Malin C Erlandsson^1,2, Lovisa Lyngfelt³, Caroline Wasén³, Sofia Töyrä Silfverswärd³, Mitra Nadali^1,3, Rille Pullerits^1,3,4 and Maria I Bokarewa¹, ¹Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, ³Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, ⁴Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Background/Purpose: Since low serum IGF1 is generally attributed to inflammation and RA severity, we analyze if serum levels of IGF1 is associated with cardiovascular (CV)…
Abstract Number: 958 • 2018 ACR/ARHP Annual Meeting
Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting
Fenglong Xie¹, Huifeng Yun¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Multiple studies have observed unfavorable changes in lipid profile associated with tocilizumab (TCZ, anti-IL6 receptor antagonists) and some other rheumatoid arthritis (RA) therapies. The…
Abstract Number: 1629 • 2018 ACR/ARHP Annual Meeting
Hyperlipoproteinemia (a) in Patients with Spondyloarthritis. Results of the CARMA Study
María Carmen García-Gómez¹, Maria Auxiliadora Martin², Cristina Fernández-Carballido³, Santos Castañeda⁴, Carlos González-Juanatey⁵, Fernando Sánchez-Alonso⁶, María José González-Fernández⁷, Raimon Sanmarti⁸, Alberto Garcia-Vadillo⁹, Benjamin Fernandez Gutierrez¹⁰, Miriam García-Arias¹¹, Javier Manero¹², José Miguel Senabre¹³, Amalia Rueda Cid¹⁴, Sergio Ros Expósito¹⁵, José Manuel Pina Salvador¹⁶, Alba Erra Durán¹⁷, Ingrid Moller¹⁸, Javier Llorca¹⁹ and Miguel Angel González-Gay²⁰, ¹Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ⁴Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁵Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Institut Dexeus, Barcelona, Spain, ⁸Rheumatology Service, Hospital Clinic, Barcelona, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁰Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹¹Hospital Universitario de la Princesa. Madrid. Spain, Madrid, Spain, ¹²Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ¹³Rheumatology, Hospital Marina Baixa, Alicante, Spain, ¹⁴Rheumatology, Hospital General de Valencia, Valencia, Spain, ¹⁵Rheumatology, Hospital de Viladecans, Barcelona, Spain, ¹⁶Rheumatology, Hospital de Barbastro, Huesca, Spain, ¹⁷Rheumatology, Hospital de Sant Rafael, Barcelona, Spain, ¹⁸Instituto de Poal, Barcelona, Spain, ¹⁹Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Santander, Spain, ²⁰School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Cardiovascular disease (CVD) is one of the main cause of mortality and morbidity in patients with spondyloarthritis (SpA), partially explained by traditional CV risk…
Abstract Number: 2242 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease
William B. White¹ and Lhanoo Gunawardhana², ¹Cardiology, University of Connecticut School of Medicine, Farmington, CT, ²Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: The Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Comorbidities (CARES) trial demonstrated that major cardiovascular (CV) outcomes on febuxostat…
Abstract Number: 301 • 2018 ACR/ARHP Annual Meeting
Rheumatology Clinic Staff Needs for Partnering to Improve Blood Pressure and Tobacco Risk Management
Michelle Tong¹, Laura Block², Andrea Gilmore-Bykovskyi², Edmond Ramly³ and Christie M. Bartels⁴, ¹Biomedical Engineering, University of Wisconsin - Madison, Madison, WI, ²University of Wisconsin School of Nursing, Madison, WI, ³Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI
Background/Purpose: Patients with rheumatologic conditions are at a higher risk of cardiovascular disease (CVD) than peers. High blood pressure (BP) and tobacco use exacerbate CVD…
Abstract Number: 514 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Risk Management in Seropositive Rheumatoid Arthritis: What Can We Do Better?
Matthew McElwee¹, Peter Boersma², Hiba Hashmi³ and Anna K. Shmagel¹, ¹Division of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ²School of Public Health, University of Minnesota, Minneapolis, MN, ³School of Medicine, University of Minnesota, Minneapolis, MN
Background/Purpose: The increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA) has been well established. While the reasons for an increased risk of CVD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.